View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsNeovasc 将来の成長Future 基準チェック /06主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長17.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジLow最終更新日10 Feb 2023今後の成長に関する最新情報Price Target Changed • Nov 16Price target decreased to US$18.00Down from US$70.50, the current price target is provided by 1 analyst. New target price is 177% above last closing price of US$6.50. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$12.15 next year compared to a net loss per share of US$9.88 last year.Price Target Changed • Apr 27Price target increased to US$5.00Up from US$3.59, the current price target is provided by 1 analyst. New target price is 1,329% above last closing price of US$0.35. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.20 next year compared to a net loss per share of US$0.40 last year.Price Target Changed • Jul 03Price target increased to US$5.00Up from US$3.59, the current price target is an average from 2 analysts. New target price is 462% above last closing price of US$0.89. Stock is down 63% over the past year.すべての更新を表示Recent updatesPrice Target Changed • Nov 16Price target decreased to US$18.00Down from US$70.50, the current price target is provided by 1 analyst. New target price is 177% above last closing price of US$6.50. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$12.15 next year compared to a net loss per share of US$9.88 last year.Reported Earnings • Nov 16Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$3.00 loss per share (further deteriorated from US$2.79 loss in 3Q 2021). Net loss: US$8.23m (loss widened 9.2% from 3Q 2021). Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) also missed analyst estimates by 6.4%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Aug 25Independent Director recently bought US$76k worth of stockOn the 19th of August, Douglas Janzen bought around 10k shares on-market at roughly US$7.63 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$257k more in shares than they have sold in the last 12 months.Reported Earnings • Aug 12Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2022 results: US$3.29 loss per share (up from US$3.35 loss in 2Q 2021). Net loss: US$8.98m (flat on 2Q 2021). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates by 39%. Over the next year, revenue is forecast to grow 309%, compared to a 6.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.Seeking Alpha • Aug 11Neovasc GAAP EPS of -$3.29 misses by $0.93, revenue of $0.82M beats by $0.13MNeovasc press release (NASDAQ:NVCN): Q2 GAAP EPS of -$3.29 misses by $0.93. Revenue of $0.82M (+30.2% Y/Y) beats by $0.13M.Seeking Alpha • Jul 05Neovasc expands direct sales operations to include the UKNeovasc (NASDAQ:NVCN) has expanded its direct sales operations in Europe to include the United Kingdom, effective July 1, 2022. The company has hired its first two direct employees in England and plans future growth in the sales team as the commercial requirements increase. The expansion is driven by NICE guidelines and enhanced reimbursement for the Neovasc Reducer™. “We are now poised to provide even deeper support with a full-time dedicated team in the U.K. and intend to continue to invest in clinical research and field personnel to support patients, physicians, and hospitals.” said Fred Colen, Neovasc President and CEO.Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$3.75 loss per share (down from US$1.11 loss in 1Q 2021). Net loss: US$10.2m (loss widened 369% from 1Q 2021). Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 200%. Over the next year, revenue is forecast to grow 425%, compared to a 8.8% growth forecast for the industry in the US.Price Target Changed • Apr 27Price target increased to US$5.00Up from US$3.59, the current price target is provided by 1 analyst. New target price is 1,329% above last closing price of US$0.35. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.20 next year compared to a net loss per share of US$0.40 last year.Reported Earnings • Mar 13Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: US$0.40 loss per share (up from US$1.72 loss in FY 2020). Net loss: US$24.9m (loss narrowed 13% from FY 2020). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 2.4%. Over the next year, revenue is forecast to grow 212%, compared to a 10% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 135% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Dec 15Chief Operating Officer recently bought US$79k worth of stockOn the 9th of December, William Little bought around 150k shares on-market at roughly US$0.53 per share. This was the largest purchase by an insider in the last 3 months. This was William's only on-market trade for the last 12 months.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.51 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$7.54m (loss narrowed 26% from 3Q 2020).Recent Insider Transactions • Aug 21Independent Director recently bought US$76k worth of stockOn the 19th of August, Douglas Janzen bought around 100k shares on-market at roughly US$0.76 per share. In the last 3 months, they made an even bigger purchase worth US$94k. Insiders have collectively bought US$305k more in shares than they have sold in the last 12 months.Reported Earnings • Aug 12Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.81 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$9.03m (loss narrowed 9.0% from 2Q 2020).Price Target Changed • Jul 03Price target increased to US$5.00Up from US$3.59, the current price target is an average from 2 analysts. New target price is 462% above last closing price of US$0.89. Stock is down 63% over the past year.Recent Insider Transactions • Jun 24Independent Director recently bought US$87k worth of stockOn the 22nd of June, Douglas Janzen bought around 100k shares on-market at roughly US$0.87 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$136k more in shares than they have sold in the last 12 months.Reported Earnings • May 09First quarter 2021 earnings released: US$0.04 loss per share (vs US$0.38 loss in 1Q 2020)First quarter 2021 results: Net loss: US$2.17m (loss narrowed 47% from 1Q 2020).Reported Earnings • Mar 14Full year 2020 earnings released: US$1.72 loss per share (vs US$5.40 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: US$1.96m (down 6.4% from FY 2019). Net loss: US$28.7m (loss narrowed 18% from FY 2019). Over the last 3 years on average, earnings per share has increased by 129% per year but the company’s share price has fallen by 78% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Mar 14Revenue and earnings miss expectationsRevenue missed analyst estimates by 2.4%. Earnings per share (EPS) also missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 136%, compared to a 21% growth forecast for the Medical Equipment industry in the US.Is New 90 Day High Low • Jan 27New 90-day high: US$1.36The company is up 28% from its price of US$1.06 on 28 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$19.91 per share.Is New 90 Day High Low • Dec 09New 90-day low: US$0.72The company is down 67% from its price of US$2.17 on 09 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Nov 13New 90-day low: US$0.75The company is down 66% from its price of US$2.17 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 08Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 225%, compared to a 16% growth forecast for the Medical Equipment industry in the US.Reported Earnings • Nov 08Third quarter 2020 earnings released: US$0.51 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: US$626.4k (up 25% from 3Q 2019). Net loss: US$10.2m (loss widened 65% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 91% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 24New 90-day low: US$2.03The company is down 22% from its price of US$2.60 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.業績と収益の成長予測NasdaqCM:NVCN - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202310-23N/AN/A112/31/20224-41-25-25N/A9/30/20223-34-24-24N/A6/30/20223-33-25-25N/A3/31/20223-33-26-25N/A12/31/20213-25-27-27N/A9/30/20212-23-30-29N/A6/30/20212-26-31-31N/A3/31/20212-27-32-31N/A12/31/20202-29-30-29N/A9/30/20202-37-29-29N/A6/30/20202-33-27-27N/A3/31/20202-31-25-25N/A12/31/20192-35-24-24N/A9/30/20192-11-24-24N/A6/30/20192-20-23-23N/A3/31/20192-61-24-24N/A12/31/20182-108-23-23N/A9/30/20182-125-141-141N/A6/30/20183-115-140-140N/A3/31/20184-71-138-138N/A12/31/20175-22-139-139N/A9/30/2017719-22-21N/A6/30/20179-5-29-28N/A3/31/20179-83-36-35N/A12/31/201610-86-40-40N/A9/30/20169-131N/A-39N/A6/30/20168-110N/A-35N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NVCNの予測収益成長が 貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NVCNの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NVCNの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NVCNの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NVCNの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NVCNの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/04/13 12:16終値2023/04/10 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Neovasc Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関David DeanATB Cormark Historical (Cormark Securities)David MartinBloom Burton & Co.Jason MillsCanaccord Genuity6 その他のアナリストを表示
Price Target Changed • Nov 16Price target decreased to US$18.00Down from US$70.50, the current price target is provided by 1 analyst. New target price is 177% above last closing price of US$6.50. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$12.15 next year compared to a net loss per share of US$9.88 last year.
Price Target Changed • Apr 27Price target increased to US$5.00Up from US$3.59, the current price target is provided by 1 analyst. New target price is 1,329% above last closing price of US$0.35. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.20 next year compared to a net loss per share of US$0.40 last year.
Price Target Changed • Jul 03Price target increased to US$5.00Up from US$3.59, the current price target is an average from 2 analysts. New target price is 462% above last closing price of US$0.89. Stock is down 63% over the past year.
Price Target Changed • Nov 16Price target decreased to US$18.00Down from US$70.50, the current price target is provided by 1 analyst. New target price is 177% above last closing price of US$6.50. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$12.15 next year compared to a net loss per share of US$9.88 last year.
Reported Earnings • Nov 16Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$3.00 loss per share (further deteriorated from US$2.79 loss in 3Q 2021). Net loss: US$8.23m (loss widened 9.2% from 3Q 2021). Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) also missed analyst estimates by 6.4%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Aug 25Independent Director recently bought US$76k worth of stockOn the 19th of August, Douglas Janzen bought around 10k shares on-market at roughly US$7.63 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$257k more in shares than they have sold in the last 12 months.
Reported Earnings • Aug 12Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2022 results: US$3.29 loss per share (up from US$3.35 loss in 2Q 2021). Net loss: US$8.98m (flat on 2Q 2021). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates by 39%. Over the next year, revenue is forecast to grow 309%, compared to a 6.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
Seeking Alpha • Aug 11Neovasc GAAP EPS of -$3.29 misses by $0.93, revenue of $0.82M beats by $0.13MNeovasc press release (NASDAQ:NVCN): Q2 GAAP EPS of -$3.29 misses by $0.93. Revenue of $0.82M (+30.2% Y/Y) beats by $0.13M.
Seeking Alpha • Jul 05Neovasc expands direct sales operations to include the UKNeovasc (NASDAQ:NVCN) has expanded its direct sales operations in Europe to include the United Kingdom, effective July 1, 2022. The company has hired its first two direct employees in England and plans future growth in the sales team as the commercial requirements increase. The expansion is driven by NICE guidelines and enhanced reimbursement for the Neovasc Reducer™. “We are now poised to provide even deeper support with a full-time dedicated team in the U.K. and intend to continue to invest in clinical research and field personnel to support patients, physicians, and hospitals.” said Fred Colen, Neovasc President and CEO.
Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$3.75 loss per share (down from US$1.11 loss in 1Q 2021). Net loss: US$10.2m (loss widened 369% from 1Q 2021). Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 200%. Over the next year, revenue is forecast to grow 425%, compared to a 8.8% growth forecast for the industry in the US.
Price Target Changed • Apr 27Price target increased to US$5.00Up from US$3.59, the current price target is provided by 1 analyst. New target price is 1,329% above last closing price of US$0.35. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.20 next year compared to a net loss per share of US$0.40 last year.
Reported Earnings • Mar 13Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: US$0.40 loss per share (up from US$1.72 loss in FY 2020). Net loss: US$24.9m (loss narrowed 13% from FY 2020). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 2.4%. Over the next year, revenue is forecast to grow 212%, compared to a 10% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 135% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Dec 15Chief Operating Officer recently bought US$79k worth of stockOn the 9th of December, William Little bought around 150k shares on-market at roughly US$0.53 per share. This was the largest purchase by an insider in the last 3 months. This was William's only on-market trade for the last 12 months.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.51 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$7.54m (loss narrowed 26% from 3Q 2020).
Recent Insider Transactions • Aug 21Independent Director recently bought US$76k worth of stockOn the 19th of August, Douglas Janzen bought around 100k shares on-market at roughly US$0.76 per share. In the last 3 months, they made an even bigger purchase worth US$94k. Insiders have collectively bought US$305k more in shares than they have sold in the last 12 months.
Reported Earnings • Aug 12Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.81 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$9.03m (loss narrowed 9.0% from 2Q 2020).
Price Target Changed • Jul 03Price target increased to US$5.00Up from US$3.59, the current price target is an average from 2 analysts. New target price is 462% above last closing price of US$0.89. Stock is down 63% over the past year.
Recent Insider Transactions • Jun 24Independent Director recently bought US$87k worth of stockOn the 22nd of June, Douglas Janzen bought around 100k shares on-market at roughly US$0.87 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$136k more in shares than they have sold in the last 12 months.
Reported Earnings • May 09First quarter 2021 earnings released: US$0.04 loss per share (vs US$0.38 loss in 1Q 2020)First quarter 2021 results: Net loss: US$2.17m (loss narrowed 47% from 1Q 2020).
Reported Earnings • Mar 14Full year 2020 earnings released: US$1.72 loss per share (vs US$5.40 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: US$1.96m (down 6.4% from FY 2019). Net loss: US$28.7m (loss narrowed 18% from FY 2019). Over the last 3 years on average, earnings per share has increased by 129% per year but the company’s share price has fallen by 78% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Mar 14Revenue and earnings miss expectationsRevenue missed analyst estimates by 2.4%. Earnings per share (EPS) also missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 136%, compared to a 21% growth forecast for the Medical Equipment industry in the US.
Is New 90 Day High Low • Jan 27New 90-day high: US$1.36The company is up 28% from its price of US$1.06 on 28 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$19.91 per share.
Is New 90 Day High Low • Dec 09New 90-day low: US$0.72The company is down 67% from its price of US$2.17 on 09 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Nov 13New 90-day low: US$0.75The company is down 66% from its price of US$2.17 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 08Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 225%, compared to a 16% growth forecast for the Medical Equipment industry in the US.
Reported Earnings • Nov 08Third quarter 2020 earnings released: US$0.51 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: US$626.4k (up 25% from 3Q 2019). Net loss: US$10.2m (loss widened 65% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 91% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 24New 90-day low: US$2.03The company is down 22% from its price of US$2.60 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.